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Use of the Randox Evidence Investigator immunoassay system for near-body drug 
screening during post-mortem examination in 261 forensic cases. 
Abstract 
Background 
This paper describes the performance of four Randox drug arrays, designed for whole blood, 
for the near-body analysis of drugs in a range of post-mortem body specimens. 
Methods 
Liver, psoas muscle, femoral blood, vitreous humor and urine from 261 post-mortem cases 
were screened in the mortuary and results were obtained within the time taken to complete a 
post-mortem. Specimens were screened for the presence of amfetamine, barbiturates, 
benzodiazepines, benzoylecgonine, buprenorphine, cannabinoids, dextropropoxyphene, 
fentanyl, ketamine, lysergide, methadone, metamfetamine, methaqualone, 3,4-
methylenedioxymetamfetamine, opioids, paracetamol, phencyclidine, salicylate, salicylic 
acid, zaleplon, zopiclone and zolpidem using the DOA I, DOA I+, DOA II and Custom arrays. 
Results 
Liver and muscle specimens were obtained from each of the 261 post-mortem cases; 
femoral blood, vitreous humor and urine were available in 98%, 92% and 72% of the cases, 
respectively. As such, the equivalent of 12,978 individual drug-specific, or drug-group, 
immunoassay tests were undertaken. Overall >98% of the 12,978 screening tests 
undertaken agreed with laboratory confirmatory tests performed on femoral blood. 
Conclusions 
There is growing interest in the development of non-invasive procedures for determining the 
cause of death using MRI and CT scanning however these procedures are, in most cases, 
unable to determine whether death may have been associated with drug use.  The Randox 
arrays can provide qualitative and semi-quantitative results in a mortuary environment 
enabling pathologists to decide whether to remove specimens from the body and submit 
them for laboratory analysis. Analysis can be undertaken on a range of autopsy specimens 
which is particularly useful when conventional specimens such as blood are unavailable. 
Keywords: Post-mortem, Toxicology, Near-body Drug Screening, Forensic Pathology, 
Laboratory Tests. 
  
Introduction 
Interest is increasing in the use of non-invasive techniques to ascertain the cause of death 
as a replacement for the traditional post-mortem examination. Magnetic resonance imaging 
(MRI) and computerised tomography (CT) scanning have been suggested in lieu of invasive 
post-mortems [1 – 3].  Whilst CT and MRI scanning may be suitable for the diagnosis of 
certain types of death there are weaknesses [3] and pathologists must still rely on the 
removal of tissue specimens for laboratory analysis before drug or poisoning related deaths 
may be identified. The removal of post-mortem tissue can be complicated by legislation or 
religious custom hence a rapid near-body screen that can provide an indication of the 
presence of drugs in a body could be beneficial. Emergency departments, drug treatment 
clinics and workplace drug testing programs already use near-body drug screening to 
determine an individual’s recent drug use [4-9] but few reports describe the use of near-body 
methodologies for post-mortem drug screening.  
Immunoassays are simple to use however the majority of drug screening immunoassays 
designed for clinical settings are not suitable for post-mortem cases as their cut-off limits are 
too high and drugs of forensic importance may be missed.  Furthermore, clinical near-patient 
tests are limited to detecting a small selection of common drugs of abuse and are also based 
on technology that requires relatively non-viscous specimens e.g. urine or oral fluid in order 
to operate. 
The Randox Evidence Investigator system relies on biochip technology rather than 
conventional lateral flow technology and is subsequently amenable for use with a wide range 
of tissue specimens. Each biochip measures 9 x 9 mm and can have up to 13 drug specific 
antibodies immobilised in predefined regions on the biochip. Chemiluminescence is 
employed to obtain semi-quantitative drug concentrations.  Light signals generated from 
each antibody site on the biochip are simultaneously detected using digital imaging 
technology and compared to that from a calibration curve. Nine biochips are mounted within 
individual wells on a single cassette enabling analysts to screen either nine different cases 
or fewer cases but a wider range of tissue specimens simultaneously. We previously 
reported on the performance of the Randox DOA I and DOA II panels in 106 forensic post-
mortems [10].  In this paper we describe the use of the DOA I, DOA I+, DOA II and a 
“Custom Array” panel to detect a range of drugs (Table 1) in a variety of post-mortem 
toxicology specimens obtained from 261 post-mortem cases. 
  
Table 1 Drugs detected using the DOA I, DOA I+, DOA II and Custom arrays 
 DOA I  
(calibration range, 
LOD) 
DOA I+ 
(calibration range, 
LOD) 
DOA II 
(calibration 
range, LOD) 
Custom 
(calibration 
range, LOD) 
Amfetamine  
(0-108 ng/mL, 1.60 
ng/mL) 
Amfetamine  
(0-108 ng/mL, 1.60 
ng/mL) 
Buprenorphine 
(0-80 ng/ml, 
normalised 
value of 71) 
Paracetamol 
(0-695 µg/mL, 
1.045 µg/mL) 
Barbiturates  
(0-356 ng/mL, 1.59 
ng/mL) 
Barbiturates  
(0-356 ng/mL, 1.59 
ng/mL) 
Dextropropoxy
phene 
(0-2000 ng/ml, 
normalised 
value of 71) 
Salicylate 
(0 - 665 µg/ml, 
0.495 µg/mL) 
Benzodiazepines Ia 
(0-244 ng/mL, 0.37 
ng/mL) 
Benzodiazepines Ia  
(0-244 ng/mL, 0.37 
ng/mL) 
Fentanyl 
(0-40 ng/ml, 
normalised 
value of 76) 
Salicylic acid 
(0 - 665 µg/ml, 
0.495 µg/mL) 
Benzodiazepines IIa  
(0-280 ng/mL, 0.29 
ng/mL) 
Benzodiazepines IIa 
(0-280 ng/mL, 0.29 
ng/mL) 
Ketamine 
(0-2000 ng/ml, 
normalised 
value of 10) 
Zaleplon 
(0 - 202 ng/mL, 
0.1 ng/mL) 
Benzoylecgonine 
(0-244 ng/mL, 0.36 
ng/mL) 
Benzoylecgonine  
(0-244 ng/mL, 0.36 
ng/mL) 
Lysergide 
(0-8000 ng/ml, 
normalised 
value of 76) 
Zolpidem 
(0 – 137 ng/ml, 
0.075 ng/mL) 
Cannabinoids  
(0-40 ng/mL, 0.98 
ng/mL) 
Buprenorphine  
(0.08 ng/mL) 
Methaqualone 
(0-500 ng/ml, 
normalised 
value of 10) 
Zopiclone 
(0 - 516 ng/mL, 
0.375 ng/mL) 
Metamfetamine 
(0-368 ng/mL, 6.75 
ng/mL) 
Cannabinoids  
(0-40 ng/mL, 0.98 
ng/mL) 
3,4-
Methylenediox
ymetamfetami
ne 
(0-4000 ng/ml, 
normalised 
value of 77) 
  
Methadone  
(0-132 ng/mL, 0.16 
ng/mL) 
Metamfetamine 
(0-368 ng/mL, 6.75 
ng/mL) 
Opioidsc 
(0-2000 ng/ml, 
normalised 
value of 53) 
  
Opiatesb  
(0-132 ng/mL, 0.09 
ng/mL) 
Methadone  
(0-132 ng/mL, 0.16 
ng/mL) 
Oxycodone Id 
(0-2000 ng/ml, 
normalised 
value of 43) 
  
Phencyclidine  
(0-48 ng/mL, 0.10 
ng/mL) 
3,4-
Methylenedioxymeta
mfetamine  
(1.93 ng/mL) 
Oxycodone IId 
(0-2000 ng/ml, 
normalised 
value of 18) 
  
  Opiatesb  
(0-132 ng/mL, 0.09 
ng/mL) 
    
  Phencyclidine  
(0-48 ng/mL, 0.10 
ng/mL) 
    
  Tricyclic 
Antidepressants  
(1.06 ng/mL) 
    
aBenzodiazepine I has high cross reactivity for oxazepam, midazolam, flunitrazepam, 
diazepam, temazepam, ethylflurazepam and clobazam whereas benzodiazepine II is specific 
for lorazepam. 
bOpiate antibody cross reacts with morphine (100%), 6-acetylmorphine (1214%), codeine 
(106%), morphine-3-glucuronide (16%) and hydromorphone (27%).  
cOpioid antibody cross reacts with hydrocodone (2282%), ethyl morphine (867%), 
hydromorphone (163%), codeine (291%), oxycodone (100%), dihydrocodeine (82%), 
thebaine (21%) and morphine (9%).    
dOxycodone I has higher cross reactivity for noroxycodone and hydrocodone compared to 
Oxycodone II. 
  
Materials and Methods 
Femoral blood, urine, vitreous humor, liver and psoas major muscle specimens were 
obtained from 261 consecutive forensic post-mortem cases carried out at the Sir James 
Black Mortuary, Dundee. Ethics permission was not necessary as the information obtained 
was included in the toxicology case report, following the guidelines by the Procurator Fiscal.  
Specimen Preparation 
Blood was collected from the ligated femoral vein and urine was syringed from the bladder 
using a 10 mL syringe. Vitreous humor was collected with a 5 mL syringe and a 19 gauge 
needle via puncture through the sclera. Body fluids were collected into tubes containing 
sodium fluoride and potassium oxalate. The liver specimen was obtained from the right lobe 
and a 1 cm3 section of the psoas major muscle was also collected. On completion of 
screening all tissue specimens, other than blood, were returned to the body. 
Liver and psoas major muscle (1 cm3; approximate weight 1 g) were cut into small pieces 
and homogenised with 1 mL of the manufacturer’s diluent. Specimens were blended to form 
a smooth homogenate using a Janke Kunkel Ultra Turrax t25 homogeniser (IKA Laboratory).  
Homogenates were centrifuged for 10 minutes at 3000 rpm and 25 µL aliquots of the 
supernatant were removed. 25 µL aliquots of blood, vitreous humor, urine, and liver and 
muscle supernatant were diluted 1:3 v/v with assay diluent as per the kit manufacturer’s 
instruction. Specimens were thoroughly mixed using a vortex mixer prior to introduction of 
the specimen onto the biochip.   
  
Immunoassay Protocol 
A two day training course was provided by Randox to operate the Evidence Investigator 
system, the protocol was as follows. Assay diluent (120 µL) was added to each biochip 
followed by either 60 µL of a calibrator, control, or specimen. A calibration curve cassette 
and quality controls (low and high), provided by Randox, for each array were run alongside 
each set of case specimens. A conjugate (120 µL) consisting of horseradish peroxidase 
labelled analytes was added to compete for specific antibodies with any drug present in the 
specimen. Biochips were then incubated and agitated at 25°C for 30 minutes at 330 rpm in a 
‘Thermoshaker’. The DOA II array protocol differs from the DOA I, DOA I+ and Custom array 
only in that the DOA II array has an incubation temperature of 30°C and an increased 
agitation of 370 rpm. Subsequent to incubation each biochip was relieved of unbound 
analytes by 6 quick washes followed by 6 two-minute soaks using the manufacturer’s wash 
buffer. Fluid remaining in the cassettes was drained onto absorbent paper. Luminol:peroxide 
signal reagent (250 µL) was added to each biochip and the cassette was protected from light 
for 2 minutes prior to insertion into the Evidence Investigator imaging system for 
measurement of the chemiluminescence reaction.  
  
Confirmation 
Confirmatory analysis of the femoral blood specimens of all 261 cases was performed at the 
Centre of Forensic and Legal Medicine toxicology laboratory (Dundee) using LC-MS/MS, 
LC-DAD and GC-MS. LC-MS/MS assay was performed using an AB Sciex 3200 Qtrap 
(Warrington, UK) with Agilent (Wokingham, UK) 1200 series HPLC system.  A Phenomenex 
Gemini column (150 mm x 2 mm) was used for analysis. A mobile phase of 3% acetonitrile 
for 3 minutes increased to 65% acetonitrile over 20 minutes was used, total run time of 23 
minutes. Mobile phase A comprised 1 mM ammonium formate and 0.1% formic acid.  Mobile 
phase B comprised 70% acetonitrile, 1 mM ammonium formate and 0.1% formic acid.  
Detection by LC-DAD was based on a previously published method [11] using a Dionex 
(Camberley, UK) HPLC system fitted with a Phenomenex Synergi 4m Fusion 150 mm x 4.6 
mm column. Data acquisition was achieved using a diode array detector recording between 
200 nm and 595 nm. 
GC-MS was performed using an Agilent (Stockport, UK) 7890A gas chromatograph 
interfaced with an Agilent 5975C mass spectrometer using an adapted version of a 
previously published method [12]. The GC conditions involved splitless injection onto a HP-
5MS column (30 m x 0.25 mm ID, 0.25 µm film thickness); injection port temperature, 175°C; 
carrier gas, helium; flow rate, 1.7 ml/min; column temperature, 60°C for 1.5 min and 
increased by 10°C /min to 220°C and held for an additional 9 min. The limit of detection 
(LOD) employed for barbiturates was 0.1 mg/L, tricyclic antidepressants, amine drugs and 
methadone 0.01 mg/L, and a LOD of 0.004 mg/L for opioids and benzodiazepines. 
 
Results 
Blood, urine, vitreous humor, liver and muscle from 261 post-mortem cases were screened 
and results were obtained within 60 minutes of the pathologist providing the necessary 
specimens. Although the Evidence Investigator is reported to be semi-quantitative, the 
calibrators and controls were designed for whole blood. Therefore the assay results obtained 
for the biological specimens were only qualitative. Validation studies would have to be 
undertaken to determine the matrix effects to allow semi-quantitative data to be reported.  
Liver and muscle specimens were obtained from all post-mortem cases whereas blood, 
vitreous humor and urine were available in 98%, 92% and 72% of the cases respectively. 
The post-mortem cases were screened using the DOA I, DOA I+, DOA II, or the custom 
array, or a combination of two arrays. In total, 1,207 biochips across the four arrays were run 
that screen for several drugs, or drug classes, simultaneously (Table 1), equating to 12,978 
individual drug/drug group screens being processed.   
 
Table 2 Summary of confirmed screening tests in different tissues compared against 
confirmed blood analysis 
  Liver Urine Muscle Blood Vitreous 
  Cases 
Confir
med 
% 
Agr
eed 
Cases 
Confir
med 
% 
Agr
eed 
Cases 
Confir
med 
% 
Agr
eed 
Cases 
Confir
med 
% 
Agr
eed 
Cases 
Confir
med 
% 
Agr
eed 
Amfetamin
e 
3 100 2 100 3 100 3 100 3 100 
Barbiturat
es 
1 100 1 100 1 100 1 100 1 100 
Benzodiaz
epines 
70 99 56 95 70 96 68 94 63 78 
Benzoylec
gonine 
1 100 1 100 1 100 1 100 1 100 
Methadon
e 
20 100 17 100 20 95 19 95 18 89 
Opiatesa 83 99 61 100 81 94 83 96 80 95 
Opioidsa 15 100 10 100 15 100 15 87 13 100 
Oxycodon
ea 
2 100 2 100 2 100 2 100 2 100 
Paraceta
mol 
12 100 7 100 12 100 12 100 11 82 
Salicylate 11 100 10 100 11 100 11 91 11 91 
Tricyclic 
Antidepres
sants 
20 100 15 100 20 95 18 94 18 89 
Comparison of the number of cases in which confirmed screening test results (cases 
confirmed) are shown against the number of results confirmed in femoral blood (% agreed) 
for liver, urine, muscle, blood and vitreous humor. aOpiates, and opioids and oxycodone not 
grouped as different antibodies were used in the DOA I+ and DOA II arrays, respectively. 
 
Of the 261 post-mortem blood specimens that underwent confirmatory analyses, 151 were 
positive for one or more analytes.  The analytes detected by confirmatory analysis in the 
blood are listed in Table 2. Opiates and benzodiazepines were the most common groups of 
drugs detected whilst barbiturates and benzoylecgonine were only infrequently encountered. 
The liver screens were in ≥ 99% agreement with confirmatory analysis, urine ≥ 95%, muscle 
≥ 94%, blood ≥ 87% and vitreous humor ≥ 78%.  
 
Table 3 Kappa analysis between the Randox microchip screening test results in different 
tissues and the gas chromatography / mass spectrometry confirmatory analysis undertaken 
on whole blood specimens. 
  Liver Muscle Blood Vitreous 
Humor 
Urine 
Amfetamine .488 .316 .414 .854 .318 
Barbiturates .664 1.00 1.00 1.00 1.00 
Benzodiazepines .945 .978 .932 .809 .956 
Benzoylecgonine 1.00 .956 1.00 1.00 1.00 
Methadone 1.00 .944 .970 .935 .967 
Opiatesa .888 .896 .958 .922 .820 
Opioidsa .871 .936 .870 .931 1.00 
Oxycodonea .783 1.00 1.00 1.00 .425 
Paracetamol .805 .684 .867 .842 .903 
Salicylate .801 .801 .784 .702 .676 
Tricyclic 
Antidepressants 
.885 .938 .901 .865 .859 
Statistical measurements using Kappa scores enables sets of data to be compared to 
observe agreement between the data sets.  Kappa scores between 0.81 -0.99 represent 
almost perfect agreement, 0.61-0.8 substantial agreement, 0.41-0.6 moderate agreement 
and 0.1 -0.2 slight agreement. aOpiates, and opioids and oxycodone not grouped as different 
antibodies were used in the DOA I+ and DOA II arrays, respectively. 
  
To take into account the possibility of chance agreement, Cohen’s Kappa testing [13] was 
undertaken. Kappa testing may be used to demonstrate the degree of agreement corrected 
for the element of chance agreement between the different screening tests and confirmatory 
analysis. Table 3 summarises the results of Kappa analysis between the Randox microchip 
screening test results in different biological specimens and confirmatory analysis undertaken 
on whole blood specimens.  
 
Table 4 Number of cases where non-concordant immunoassay results were obtained 
  Liver Muscle Blood Vitreous  Urine 
Amfetamine 6 12 8 1 8 
Barbiturates 1 -  -  - -  
Benzodiazepines 4 1 2 1 -  
Metamfetamine 9 8 5 2 11 
Methadone - 1 - - 1 
3,4-
Methylenedioxymetamfetamin
e 
10 9 1 1 7 
Opiatesa 10 3 1 3 13 
Opioidsa 2 1 - 1 -  
Oxycodonea 1 - - - 4 
Paracetamol 3 5 2 - 1 
Salicylic acid 3 3 2 3 4 
Tricyclic antidepressants 4 1 2 2 4 
Total discrepancies (false 
positives) excluding THCb 
53 
  
44 
  
24 
  
14 
  
53 
  
Percentage of tests that 
disagreed with confirmatory 
analysis, false positives 
(excluding THCb) 
2.0% 1.7% 0.9% 0.6% 2.8% 
Percentage of tests that 
disagreed with confirmatory 
analysis, false positives and 
false negatives (excluding 
THCb) 
2.1% 2.0% 1.4% 1.6% 2.9% 
aOpiates, and opioids and oxycodone not grouped as different antibodies were used in the 
DOA I+ and DOA II arrays, respectively. bTHC Tetrahydrocannabinol - analyte that gives a 
positive indicator for cannabinoids.  
 
  
Non-concordant immunoassay results were detected <3% of the post-mortem specimens 
(Table 4).   Liver and urine had the greatest occurrence of additional positives compared to 
their respective confirmed blood specimen, followed by muscle, blood and vitreous humor. 
False positive immunoassay results were detected in <1% of all blood specimens tested.  
 
In addition to the drugs listed in Table 2, cannabinoids were also detected using the DOA I 
and DOA I+ array. One or more tissue specimens obtained from 33 post-mortem cases gave 
positive cannabinoid screens, however confirmatory analysis for cannabinoids was not 
undertaken and therefore these results could not be included in Table 4.  
 
Although the test systems evaluated were reported to be capable of detecting 
buprenorphine, dextropropoxyphene, fentanyl, ketamine, lysergide, methaqualone, PCP, 
salicylic acid, zaleplon, zopiclone or zolpidem, no cases were encountered during the study 
period where these drugs were deemed present by the confirmatory methods. In addition, no 
false positives were obtained for the aforementioned drugs.  
  
Discussion 
Tissue selection for toxicological analysis during a post-mortem examination is dictated by 
availability and whilst analysis of peripheral blood specimens is the preferred option for 
interpretative purposes, alternative specimens are important in cases where blood may not 
be available. In putrefied bodies blood or urine may not be available and muscle may be less 
affected than liver or other tissues.  For interpretation peripheral blood is the desired 
specimen however, if no blood is obtainable liver is an excellent tissue for providing 
evidence of drug use as it is the major organ in the body where drugs are metabolised. 
Vitreous humor is particularly useful as a tissue for drug analysis in bodies subjected to 
major trauma although much has still to be learned concerning the relationship of drugs in 
this tissue to that in other tissues.  In this study we therefore investigated the use of a 
microchip screening technique to observe how it would perform using a variety of different 
post-mortem tissues. 
The routine procedure employed at the Centre of Forensic and Legal Medicine (Dundee) 
was to perform confirmatory analysis on blood only.  In cases where blood is unavailable an 
alternative tissue is analysed.  Since only blood was used for confirmatory analysis, an 
assumption was made that where a positive screening result was observed in urine, vitreous 
humor, liver and muscle, the blood could be used to corroborate the screening result.  
Excellent correlation was observed between blood confirmation and liver and urine 
screening results (Table 2).  This is not surprising because liver is the principal organ 
responsible for drug metabolism and urine has a long drug detection window.  Muscle and 
blood also presented excellent overall agreement with the confirmatory results.  In the cases 
where positive correlation between screening and confirmatory analysis in blood and muscle 
was not observed it was noted that the blood drug concentrations were usually close to cut-
off and patient case histories indicated infrequent or low drug consumption. Vitreous humor 
screening results were the most varied, agreement with confirmatory analyses ranged from 
78-100%. However the Kappa analysis (Table 3) shows that there was almost perfect 
agreement between screening and confirmatory analysis for the majority of drugs, with 
amfetamine being the exception; scores between 0.81-0.99 represent almost perfect 
agreement, 0.61-0.8 substantial agreement, 0.41-0.6 moderate agreement and 0.1-0.2 slight 
agreement [13].  
 
In general the additional drug positives (Table 4) could be supported by the individual’s case 
history with the exception of amine based drugs, and paracetamol and aspirin (indicated by 
salicylate, salicylic acid) as their use was not always recorded. The majority of non-
concordant results were attributed to cross reaction between putrefactive amines and the 
amfetamine antibody. False positives for amfetamine, metamfetamine and 3,4-
methylenedioxymetamfetamine occurred in blood specimens from decedents who were left 
undiscovered for a number of weeks or were located in a warm environment. Urine, liver and 
muscle were also adversely affected by putrefactants, as shown by GC/MS, however few 
false positive amfetamine, metamfetamine and 3,4-methylenedioxymetamfetamine results 
were obtained in vitreous humor specimens. In general fewer presumed false positives were 
detected in vitreous humor compared to blood, muscle, liver and urine (0.6% compared to 
0.9%, 1.7%, 2.0% and 2.8% respectively). This is most likely due to the isolated 
compartment in which vitreous humor is located and the selectivity of the tissue membrane. 
The selectivity of the vitreous membrane may also inhibit or delay the incorporation of some 
drugs into eye fluid could offer a possible explanation for the lower agreement of vitreous 
humor screening results with confirmation analysis. Cannabinoids were detected in 33 post-
mortem cases and although no confirmatory analysis was undertaken to detect 
cannabinoids, good agreement was observed between screening results and the decedent’s 
case history where individuals were reported to be cannabis users. Cannabinoids were 
detected consistently in liver, muscle, blood and urine; however its presence was relatively 
infrequent in vitreous humor specimens. Only 2 out of 31 cases where vitreous humor was 
available gave positive screening tests for cannabinoids. In these 2 cases the blood, urine, 
liver and muscle specimens yielded high semi-quantitative concentrations (greater than the 
calibration range). This finding was also observed by Jenkins and O’Block [14] who reported 
positive cannabinoid vitreous humor results only when high concentrations were detected in 
the related blood specimen. 
  
Conclusion 
The Randox DOA I,  I+, II and Custom array drug screening panels offer pathologists and 
toxicologists the opportunity to screen a range of tissue specimens for the presence of 
common therapeutic and abused drugs, specifically those listed in Table 2. As many drugs 
on the four arrays were not detected by confirmatory analysis, comments cannot be made 
on their ability to detect true positives, however the lack of false positives can be commented 
upon. The screening procedure is simple, sufficiently sensitive to make it appropriate for use 
in forensic toxicology, and the speed with which the assay can be completed enables a drug 
screen to be undertaken whilst an autopsy is in progress. The assays may be used to screen 
blood, urine, liver, vitreous humor and muscle enabling their use in cases where 
conventional specimens may be unavailable e.g. fire deaths or decomposed bodies. 
Excellent agreement for the presence of amfetamines, barbiturates, benzodiazepines, 
cocaine derivatives, methadone, opioids, paracetamol, salicylate and tricyclic 
antidepressants in liver, urine, blood and muscle were obtained between the near-body 
screening test and laboratory analysis of femoral blood specimens. Although confirmatory 
analysis for the presence of cannabinoids was not undertaken, the cases where 
cannabinoids were detected by the screening tests were corroborated by case histories. 
Vitreous fluid showed poorer correlation between the screening test and confirmatory 
analysis on blood however it is recognised that a number of factors can influence the 
passage of drugs into eye fluid.  
An indication of the presence or absence of drugs in a body whilst the post-mortem is being 
undertaken could influence the pathologist in deciding whether to remove organs for 
laboratory analysis, reducing the cost of death investigation and simplifying procedures 
associated with the Human Tissue Act. 
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